XNASLUCD
Market cap51mUSD
Jan 08, Last price
0.86USD
1D
-4.46%
1Q
9.68%
IPO
-90.81%
Name
Lucid Diagnostics Inc
Chart & Performance
P/E
—
P/S
21.01
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
2.45%
Rev. gr., 5y
%
Revenues
2m
+544.03%
Net income
-53m
L-6.24%
CFO
-33m
L+10.55%
Earnings
Mar 24, 2025
Profile
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 2,428 544.03% | 377 -24.60% | ||||
Cost of revenue | 48,889 | 54,899 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (46,461) | (54,522) | ||||
NOPBT Margin | ||||||
Operating Taxes | 1,708 | |||||
Tax Rate | ||||||
NOPAT | (46,461) | (56,230) | ||||
Net income | (52,666) -6.24% | (56,171) 95.47% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 284 | 111,611 | ||||
BB yield | -0.48% | -226.88% | ||||
| Debt | ||||||
Debt current | 15,056 | 962 | ||||
Long-term debt | 1,504 | 3,036 | ||||
Deferred revenue | ||||||
Other long-term liabilities | (1) | |||||
Net debt | (2,336) | (18,476) | ||||
| Cash flow | ||||||
Cash from operating activities | (32,817) | (29,685) | ||||
CAPEX | (221) | (908) | ||||
Cash from investing activities | (221) | (4,108) | ||||
Cash from financing activities | 29,460 | 2,611 | ||||
FCF | (45,502) | (58,859) | ||||
| Balance | ||||||
Cash | 18,896 | 22,474 | ||||
Long term investments | ||||||
Excess cash | 18,775 | 22,455 | ||||
Stockholders' equity | (18,757,074) | (98,034) | ||||
Invested Capital | 18,769,082 | 123,080 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 41,756 | 36,172 | ||||
Price | 1.41 3.68% | 1.36 -74.67% | ||||
Market cap | 58,876 19.68% | 49,194 -73.76% | ||||
EV | 75,165 | 30,718 | ||||
EBITDA | (43,962) | (52,586) | ||||
EV/EBITDA | ||||||
Interest | 416 | 8 | ||||
Interest/NOPBT | ||||||